These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 29945742)

  • 1. On-treatment lipid profiles to predict the cardiovascular outcomes in ASCVD patients comorbid with chronic kidney disease - The multi-center T-SPARCLE registry study.
    Ho LT; Lin FJ; Tseng WK; Yin WH; Wu YW; Li YH; Yeh HI; Chen JW; Wu CC;
    J Formos Med Assoc; 2018 Sep; 117(9):814-824. PubMed ID: 29945742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2017 Taiwan lipid guidelines for high risk patients.
    Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
    J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipids, Apolipoproteins, and Risk of Atherosclerotic Cardiovascular Disease in Persons With CKD.
    Bajaj A; Xie D; Cedillo-Couvert E; Charleston J; Chen J; Deo R; Feldman HI; Go AS; He J; Horwitz E; Kallem R; Rahman M; Weir MR; Anderson AH; Rader DJ;
    Am J Kidney Dis; 2019 Jun; 73(6):827-836. PubMed ID: 30686529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid profiles and risk of major adverse cardiovascular events in CKD and diabetes: A nationwide population-based study.
    Lee Y; Park S; Lee S; Kim Y; Kang MW; Cho S; Park S; Han K; Kim YC; Han SS; Lee H; Lee JP; Joo KW; Lim CS; Kim YS; Kim DK
    PLoS One; 2020; 15(4):e0231328. PubMed ID: 32271842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid lowering therapy in patients with atherosclerotic cardiovascular diseases: Which matters in the real world? Statin intensity or low-density lipoprotein cholesterol level? ‒ Data from a multicenter registry cohort study in Taiwan.
    Yeh YT; Yin WH; Tseng WK; Lin FJ; Yeh HI; Chen JW; Wu YW; Wu CC;
    PLoS One; 2017; 12(10):e0186861. PubMed ID: 29073192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective examination of lipid-lowering treatment patterns in a real-world high-risk cohort in the UK in 2014: comparison with the National Institute for Health and Care Excellence (NICE) 2014 lipid modification guidelines.
    Steen DL; Khan I; Ansell D; Sanchez RJ; Ray KK
    BMJ Open; 2017 Feb; 7(2):e013255. PubMed ID: 28213597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temporal changes in statin prescription and intensity at discharge and impact on outcomes in patients with newly diagnosed atherosclerotic cardiovascular disease-Real-world experience within a large integrated health care system: The IMPRES study.
    Anderson JL; Knowlton KU; May HT; Bair TL; Armstrong SO; Lappé DL; Muhlestein JB
    J Clin Lipidol; 2018; 12(4):1008-1018.e1. PubMed ID: 29703626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controversies Regarding Lipid Management and Statin Use for Cardiovascular Risk Reduction in Patients With CKD.
    Markossian T; Burge N; Ling B; Schneider J; Pacold I; Bansal V; Leehey D; Stroupe K; Chang A; Kramer H
    Am J Kidney Dis; 2016 Jun; 67(6):965-77. PubMed ID: 26943983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum Lipid Goal Attainment in Chronic Kidney Disease (CKD) Patients under the Japan Atherosclerosis Society (JAS) 2012 Guidelines.
    Shimizu R; Torii H; Yasuda D; Hiraoka Y; Kitada N; Hashida T; Yoshimoto A; Kita T; Kume N
    J Atheroscler Thromb; 2015; 22(9):949-57. PubMed ID: 25843151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Residual Risk Factors to Predict Major Adverse Cardiovascular Events in Atherosclerotic Cardiovascular Disease Patients with and without Diabetes Mellitus.
    Lin FJ; Tseng WK; Yin WH; Yeh HI; Chen JW; Wu CC
    Sci Rep; 2017 Aug; 7(1):9179. PubMed ID: 28835613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context.
    Toth PP; Danese M; Villa G; Qian Y; Beaubrun A; Lira A; Jansen JP
    J Med Econ; 2017 Jun; 20(6):555-564. PubMed ID: 28097904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The low-density lipoprotein cholesterol lowering is an ineffective surrogate marker of statin responsiveness to predict cardiovascular outcomes: The 10-year experience of matched population (a STROBE-compliant article).
    Hyun MH; Jang JW; Choi BG; Na JO; Choi CU; Kim JW; Kim EJ; Rha SW; Park CG; Lee E; Seo HS
    Medicine (Baltimore); 2019 Dec; 98(51):e18510. PubMed ID: 31861037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statin dose titration patterns and subsequent major cardiovascular events in very high-risk patients: estimates from Swedish population-based registry data.
    Banefelt J; Lindh M; Svensson MK; Eliasson B; Tai MH
    Eur Heart J Qual Care Clin Outcomes; 2020 Oct; 6(4):323-331. PubMed ID: 32239140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The waist-to-body mass index ratio as an anthropometric predictor for cardiovascular outcome in subjects with established atherosclerotic cardiovascular disease.
    Hsuan CF; Lin FJ; Lee TL; Yang KC; Tseng WK; Wu YW; Yin WH; Yeh HI; Chen JW; Wu CC;
    Sci Rep; 2022 Jan; 12(1):804. PubMed ID: 35039542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is non-HDL-cholesterol a better predictor of long-term outcome in patients after acute myocardial infarction compared to LDL-cholesterol? : a retrospective study.
    Wongcharoen W; Sutthiwutthichai S; Gunaparn S; Phrommintikul A
    BMC Cardiovasc Disord; 2017 Jan; 17(1):10. PubMed ID: 28056802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum Low-Density Lipoprotein Cholesterol and Cardiovascular Disease Risk Across Chronic Kidney Disease Stages (Data from 1.9 Million United States Veterans).
    Hashemi L; Hsiung JT; Arif Y; Soohoo M; Jackson N; Gosmanova EO; Budoff M; Kovesdy CP; Kalantar-Zadeh K; Streja E
    Am J Cardiol; 2022 May; 170():47-55. PubMed ID: 35300833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world cardiovascular disease burden in patients with atherosclerotic cardiovascular disease: a comprehensive systematic literature review.
    Cherepanov D; Bentley TGK; Hsiao W; Xiang P; O'Neill F; Qian Y; Yurgin N; Beenhouwer D
    Curr Med Res Opin; 2018 Mar; 34(3):459-473. PubMed ID: 29105492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HDL-C: role as a risk modifier.
    Barter P
    Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and risk of major adverse cardiovascular events in middle-aged patients with chronic kidney disease: a population-based cohort study.
    Chen S; Hsu WY; Lin YN; Wang CY; Wu CH; Chang KH
    Int Urol Nephrol; 2019 Jul; 51(7):1219-1227. PubMed ID: 31020627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.